PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Regulatory

Crown Bioscience achieves second CLIA certification of 2025 at Suzhou Laboratory

Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability and quality
Regulatory

TurboFil offers industry-leading glove testing systems

Partnership with RAVONA delivers precision and compliance in aseptic environments
Manufacturing

How to execute a successful remediation strategy

NSF’s experts share guidance on building sustainable compliance and avoiding quick fixes
Manufacturing

How to optimise your quality culture and maturity for success

NSF outlines how aligning culture, leadership and systems can strengthen compliance and performance
Regulatory

Compliance ≠ Quality: why “meeting the standard” isn’t enough

In pharma manufacturing, regulatory compliance is non-negotiable. Whether it’s 21 CFR Part 11, EU Annex 11, or PIC/S PE-009, every manufacturer understands the need for validated systems, traceable records, and secure data
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Subscribe now